Tue | Jul 27, 2021

Pfizer COVID-19 shot expanded to US children as young as 12

Published:Tuesday | May 11, 2021 | 9:40 AM
This January 24, 2021, file photo shows a vial of the Pfizer vaccine for COVID-19 in Seattle. US regulators on Monday, May 10, 2021, expanded use of Pfizer's shot to those as young as 12, sparking a race to protect middle and high school students before they head back to class in the fall. (AP Photo/Ted S. Warren, File)

United States regulators on Monday expanded the use of Pfizer's COVID-19 vaccine to children as young as 12, offering a way to protect the nation's adolescents before they head back to school in the fall and paving the way for them to return to more normal activities.

Shots could begin as soon as Thursday, after a federal vaccine advisory committee issues recommendations for using the two-dose vaccine in 12- to 15-year-olds.

An announcement is expected Wednesday.

Most COVID-19 vaccines worldwide have been authorised for adults.

Pfizer's vaccine is being used in multiple countries for teens as young as 16, and Canada recently became the first to expand use to 12 and up.

Parents, school administrators, and public health officials elsewhere have eagerly awaited approval for the shot to be made available to more kids.

“This is a watershed moment in our ability to fight back the COVID-19 pandemic,” Dr Bill Gruber, a Pfizer senior vice president who's also a pediatrician, told The Associated Press.

The Food and Drug Administration declared that the Pfizer vaccine is safe and offers strong protection for younger teens based on testing of more than 2,000 US volunteers ages 12 to 15.

The agency noted there were no cases of COVID-19 among fully vaccinated adolescents compared with 16 among kids given dummy shots.

More intriguing, researchers found the kids developed higher levels of virus-fighting antibodies than earlier studies measured in young adults.

The younger teens received the same vaccine dosage as adults and had the same side effects, mostly sore arms and flu-like fever, chills or aches that signal a revved-up immune system, especially after the second dose.

Pfizer's testing in adolescents “met our rigorous standards,” FDA vaccine chief Dr Peter Marks said.

“Having a vaccine authorized for a younger population is a critical step in continuing to lessen the immense public health burden caused by the COVID-19 pandemic.”

Pfizer and its German partner BioNTech recently requested similar authorisation in the European Union, with other countries to follow.

The latest news is welcome for US families struggling to decide what activities are safe to resume when the youngest family members remain unvaccinated.

Follow The Gleaner on Twitter and Instagram @JamaicaGleaner and on Facebook @GleanerJamaica. Send us a message on WhatsApp at 1-876-499-0169 or email us at onlinefeedback@gleanerjm.com or editors@gleanerjm.com.